Trial Profile

A Phase IIb, Multi-Centre, Randomised, Double-Blind, Active-Controlled Trial Comparing the Neuropsychiatric Adverse Event Profile of Etravirine 400mg qd Versus Efavirenz 600mg qd in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in ARV Therapy-naive HIV-1 Infected Subjects.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 05 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Etravirine (Primary) ; Efavirenz; Nucleoside reverse transcriptase inhibitors
Indications HIV-1 infections
Focus Adverse reactions
Acronyms SENSE
Sponsors Janssen-Cilag

02 Jun 2012 Company added in association field as reported by European Clinical Trials Database.
29 Dec 2011 Results assessing the effects of treatment on serum lipids published in the Journal of Antimicrobial Chemotherapy.
30 Aug 2011 48 week results published in the journal AIDS.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com